T. Rowe Price Associates
ANRO icon

T. Rowe Price Associates’s Alto Neuroscience ANRO Stock Holding History

T. Rowe Price Associates’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.46M Sell
358,279
-12,929
-3% -$299K ﹤0.01% 1346
2026
Q1 		$8.35M Buy
371,208
+340,980
+1,128% +$6.32M ﹤0.01% 1256
2025
Q4 		$539K Sell
30,228
-29,200
-49% -$368K ﹤0.01% 2360
2025
Q3 		$239K Hold
59,428
– – ﹤0.01% 2718
2025
Q2 		$131K Buy
59,428
+5,499
+10% +$13.1K ﹤0.01% 2839
2025
Q1 		$117K Sell
53,929
-790,894
-94% -$2.83M ﹤0.01% 2789
2024
Q4 		$3.58M Buy
844,823
+36,319
+4% +$227K ﹤0.01% 1392
2024
Q3 		$9.25M Buy
808,504
+162,672
+25% +$1.99M ﹤0.01% 1151
2024
Q2 		$6.9M Buy
645,832
+8,228
+1% +$107K ﹤0.01% 1167
2024
Q1 		$9.79M Buy
+637,604
New +$9.98M ﹤0.01% 1114

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

T. Rowe Price Associates's ANRO Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Alto Neuroscience (ANRO) stake by 3.5% in Q2 2026, selling an estimated $299K and leaving 358,279 shares worth $9.46M. The position accounts for ﹤0.01% of the portfolio, ranked #1346.

T. Rowe Price Associates first reported a position in ANRO in Q1 2024 and has held it in 10 quarters since. The position peaked at $9.79M in Q1 2024. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • T. Rowe Price Associates held 358,279 shares of Alto Neuroscience worth $9.46M as of Q2 2026.
  • T. Rowe Price Associates sold 12,929 Alto Neuroscience shares in Q2 2026, an estimated $299K.
  • Alto Neuroscience made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1346 holding.
  • T. Rowe Price Associates first reported a position in Alto Neuroscience in Q1 2024 and has held it in 10 quarters since.
  • T. Rowe Price Associates's Alto Neuroscience position peaked at $9.79M in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.